The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
I am a cardiovascular scientist and interventional cardiologist using biotechnological, molecular and cell biological methods as well as in vivo and ex vivo models to address translational research questions in the fields of inflammation, thrombosis and atherosclerosis. The aim of my research is to better understand the pathogenesis of cardiovascular disease and to develop new diagnostic and therapeutic strategies that ultimately provide direct benefits to patients.
Delivering Nanoparticles To Prevent Rupture Of Unstable Arterial Plaques
Funder
National Health and Medical Research Council
Funding Amount
$613,652.00
Summary
The aim of this project is to develop an immune-mediated ‘smart bomb’ concept of drug delivery into atherosclerotic plaques for the prevention of plaque rupture. An overwhelming majority of fatal heart attacks and sudden death all over the world result from plaque rupture; making this research highly important in finding a bio-technologically advanced way of preventing heart attacks and sudden death in patients with coronary artery disease.
Developing Functionalised Microbubbles For Molecular Ultrasound Imaging And Targeted Delivery Of Drugs And MicroRNA Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$677,229.00
Summary
We aim to develop gas-filled microbubbles that are directed to markers of thrombosis and inflammation and will allow visualisation of blood clots and early inflammatory reactions via ultrasound. This will allow early and timely treatment. We will systematically test for the best method of microbubble coating with recombinant antibodies in various animal models of thrombosis and inflammation. In addition, we plan to load microbubbles with drugs and target these to areas where they are needed.
Novel Selective Anti-platelet And Clot-specific Anticoagulant Strategies Targeting Conformational States Of GPIIb/IIIa
Funder
National Health and Medical Research Council
Funding Amount
$496,517.00
Summary
The inhibition of platelets and the inhibition of coagulation factors are among the most widely used drugs in medicine and provide major benefits for numerous patients. Prevention and treatment of thrombosis, emboli, stroke and heart attack are examples of the many diseases where anti-platelet and anticoagulant drugs are administered. However, the downsides of these drugs are bleeding complications, which can result in death or disability. The consequences of these drug-associated bleeding compl ....The inhibition of platelets and the inhibition of coagulation factors are among the most widely used drugs in medicine and provide major benefits for numerous patients. Prevention and treatment of thrombosis, emboli, stroke and heart attack are examples of the many diseases where anti-platelet and anticoagulant drugs are administered. However, the downsides of these drugs are bleeding complications, which can result in death or disability. The consequences of these drug-associated bleeding complications are also a major financal burden for our health care system. Thus, progress towards therapeutic strategies with less bleeding complications is highly sought-after. The proposed project aims to generate new antibody-based agents for platelet inhibition. One group of these agents do only block platelets when they are activated. Furthermore, these agents allow an enrichment of potent inhibitors of coagulation factors at the site of the clot. Thus, these inhibitors should predominatly act at the site where they are needed. At the same time the overall concentration of inhibitors of coagulation factors can be kept low and the functions of non-activated platelet can be left intact. Overall, the proposed project aims for the development of novel anti-platelet and anticoagulant strategies with high anti-thrombotic efficacy and low bleeding risks.Read moreRead less
Biophysical identification of natural human antibody targets. A natural human antibody, PAT-SM6, isolated using technology developed by the partner organisation (Patrys), offers promise as a therapy to reduce mortalities due to cancer, the leading cause of death in Australia. The novelty of the approach pioneered by Patrys is the direct production of human antibodies which avoids undesirable side effects associated with the use of antibodies containing non-human components. This project is to ....Biophysical identification of natural human antibody targets. A natural human antibody, PAT-SM6, isolated using technology developed by the partner organisation (Patrys), offers promise as a therapy to reduce mortalities due to cancer, the leading cause of death in Australia. The novelty of the approach pioneered by Patrys is the direct production of human antibodies which avoids undesirable side effects associated with the use of antibodies containing non-human components. This project is to discover the specificity of PAT-SM6 for proteins and protein complexes and how these interactions lead to tumour cell death. This work will enhance the effectiveness of human antibody therapies and help in the development of this fast growing area within the biotechnology industry in Australia.Read moreRead less